Company Overview and News

 
STO / Statoil ASA FORM 6-K (Current Report of Foreign Issuer)

2018-09-19 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EX
STO

 
STO / Statoil ASA FORM 6-K (Current Report of Foreign Issuer)

2018-09-17 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EX
STO

 
STO / Statoil ASA FORM 6-K (Current Report of Foreign Issuer)

2018-09-10 sec.gov
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STO

 
STO / Statoil ASA 424B2 (Prospectus)

2018-09-06 sec.gov
424B2 Table of Contents Filed pursuant to Rule 424(b)2 Registration Statement Nos. 333-221130 and 333-221130-01 CALCULATION OF REGISTRATION FEE
STO

 
STO / Statoil ASA 424B2 (Prospectus)

2018-09-06 sec.gov
424B2 Table of Contents Filed pursuant to Rule 424(b)2 Registration Statement Nos. 333-221130 and 333-221130-01 CALCULATION OF REGISTRATION FEE
STO

 
STO / Statoil ASA FWP

2018-09-05 sec.gov
FWP Free Writing Prospectus dated September 2, 2018 (to the prospectus dated October 26, 2017 and Preliminary Prospectus Supplement dated September 5, 2018) Filed Pursuant to Rule 433
STO

 
STO / Statoil ASA FORM 6-K (Current Report of Foreign Issuer)

2018-09-05 sec.gov
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STO

 
STO / Statoil ASA 424B2 (Prospectus)

2018-09-05 sec.gov
424B2 Table of Contents Filed pursuant to Rule 424(b)2 Registration Statement Nos. 333-221130 and 333-221130-01 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been declared effecti
STO

 
STO / Statoil ASA 424B2 (Prospectus)

2018-09-05 sec.gov
424B2 Table of Contents Filed pursuant to Rule 424(b)2 Registration Statement Nos. 333-221130 and 333-221130-01 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been declared effecti
STO

 
STO / Statoil ASA 6-K (Current Report of Foreign Issuer)

2018-09-05 sec.gov
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
STO

 
STO / Statoil ASA FORM 6-K (Current Report of Foreign Issuer)

2018-09-04 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EX
STO

 
STO / Statoil ASA FORM 6-K (Current Report of Foreign Issuer)

2018-08-28 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EX
STO

4
Equinor DCF Model: Cash Flow And Production Inspire Confidence

2018-08-27 seekingalpha
Equinor’s production has been growing from year to year, promising 3-4% CAGR in 2018-2020, while the firm’s production and drilling costs are among the lowest in the industry.
RDS.B RDS.A DTK RDSB TOT RDSA BP CVX RYDBF STOHF RYDAF STO EQNR

 
Sverdrup Was Norway's Lifeline during Oil Crash

2018-08-23 rigzone
(Bloomberg) -- Right before Norway’s biggest oil project in decades got the go-ahead in 2015, crude prices fell off a cliff. That turned out to be perfect timing.
LNDNY KVAEF LUPEY STOHF LNDNF STO

 
STO / Statoil ASA FORM 6-K (Current Report of Foreign Issuer)

2018-08-21 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EX
STO

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to STO / Statoil ASA on message board site Silicon Investor.

Uranium Stocks Uranium Stocks Uranium Stocks Technology Stocks u0026 Market Talk With Don Wolanchuk Technology Stocks u0026 Market Talk With Don Wolanchuk Technology Stocks u0026 Market Talk With Don Wolanchuk
Natural Resource Stocks Natural Resource Stocks Natural Resource Stocks [email protected] HotStove Club [email protected] HotStove Club [email protected] HotStove Club
Low Price/Cash Ratio Value Stocks Low Price/Cash Ratio Value Stocks Low Price/Cash Ratio Value Stocks Marijuana Stocks Marijuana Stocks Marijuana Stocks
Stock Watcheru0027s Thread / Pix of the Week (POW) Stock Watcheru0027s Thread / Pix of the Week (POW) Stock Watcheru0027s Thread / Pix of the Week (POW) jerseyfish penny stocks jerseyfish penny stocks jerseyfish penny stocks
Microcap Kitchen Canadian Stocks Microcap Kitchen Canadian Stocks Microcap Kitchen Canadian Stocks The Microcap Kitchen: Stocks 5�� to $5 The Microcap Kitchen: Stocks 5�� to $5 The Microcap Kitchen: Stocks 5�� to $5
CUSIP: 85771P102